RU94031753A - Производные фенилалканоламина - Google Patents

Производные фенилалканоламина

Info

Publication number
RU94031753A
RU94031753A RU94031753/04A RU94031753A RU94031753A RU 94031753 A RU94031753 A RU 94031753A RU 94031753/04 A RU94031753/04 A RU 94031753/04A RU 94031753 A RU94031753 A RU 94031753A RU 94031753 A RU94031753 A RU 94031753A
Authority
RU
Russia
Prior art keywords
hydrogen
hydroxy
formula
phenylalkanol
amine derivatives
Prior art date
Application number
RU94031753/04A
Other languages
English (en)
Inventor
Мохакси Эрно
Us]
Филип О'Бриен Джей
Original Assignee
Ф.Хоффманн-Ля Рош Аг (Ch)
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг (Ch), Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг (Ch)
Publication of RU94031753A publication Critical patent/RU94031753A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Table Devices Or Equipment (AREA)
  • Fats And Perfumes (AREA)
  • Organic Insulating Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)
  • Indole Compounds (AREA)

Abstract

Соединения формулы I, приведенной в описании, или их диастереомеры или энантиомеры, за исключением R,R-дистереомера формулы I, или их фармацевтически приемлемые соли уменьшают нежелательное воздействие от токсического повреждения центральных нейронов, вследствие чего применимы для лечения ишемии, шока, гипоксии и т.п.

Claims (1)

  1. Соединения формулы I, приведенной в описании, или их диастереомеры или энантиомеры, за исключением R,R-дистереомера формулы I, или их фармацевтически приемлемые соли уменьшают нежелательное воздействие от токсического повреждения центральных нейронов, вследствие чего применимы для лечения ишемии, шока, гипоксии и т.п.
RU94031753/04A 1993-09-02 1994-09-01 Производные фенилалканоламина RU94031753A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11638593A 1993-09-02 1993-09-02
US116.385 1993-09-02

Publications (1)

Publication Number Publication Date
RU94031753A true RU94031753A (ru) 1996-07-20

Family

ID=22366865

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94031753/04A RU94031753A (ru) 1993-09-02 1994-09-01 Производные фенилалканоламина

Country Status (22)

Country Link
EP (1) EP0648744B1 (ru)
JP (1) JP2610784B2 (ru)
KR (1) KR100360954B1 (ru)
CN (1) CN1061035C (ru)
AT (1) ATE162520T1 (ru)
AU (1) AU7149794A (ru)
BR (1) BR9403418A (ru)
CA (1) CA2129771C (ru)
CZ (1) CZ210694A3 (ru)
DE (1) DE69408078T2 (ru)
DK (1) DK0648744T3 (ru)
ES (1) ES2113585T3 (ru)
FI (1) FI107607B (ru)
GR (1) GR3026622T3 (ru)
HU (1) HUT70558A (ru)
IL (1) IL110812A0 (ru)
NO (1) NO943231L (ru)
NZ (1) NZ264320A (ru)
PL (1) PL304863A1 (ru)
RU (1) RU94031753A (ru)
TW (1) TW281670B (ru)
ZA (1) ZA946529B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2649406C1 (ru) * 2017-09-21 2018-04-03 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) 3-n-замещенные борнилпропионаты, используемые в качестве ингибиторов вируса марбург

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658909A (en) * 1994-11-17 1997-08-19 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat Alzheimer's Disease
US5693804A (en) * 1994-11-17 1997-12-02 Molecular Geriatrics Corporation Substituted 1-aryl-3-piperazin-1'-yl propanones
US6214994B1 (en) 1997-04-21 2001-04-10 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1′-yl propanones
FR2742051B1 (fr) * 1995-12-06 1998-02-06 Synthelabo Utilisation de composes ayant une affinite pour le site de liaison du (3h)ifenprodil pour la fabrication de medicaments utiles dans la prevention et le traitement des neuropathies
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
BR9814867A (pt) 1997-10-24 2000-10-03 Warner Lambert Co Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
PL216636B1 (pl) * 2001-07-24 2014-04-30 Richter Gedeon Vegyészeti Gyár RT Pochodne amidów kwasów karboksylowych, środek farmaceutyczny, sposób wytwarzania pochodnych amidów kwasów karboksylowych, sposób wytwarzania środka farmaceutycznego i zastosowanie pochodnych amidów kwasów karboksylowych
US7786140B2 (en) 2003-09-25 2010-08-31 Shionogi & Co., Ltd. Piperidine derivative having NMDA receptor antagonistic activity
RU2638807C2 (ru) 2011-11-22 2017-12-15 Те Риджентс Оф Те Юниверсити Оф Калифорния Способы и композиции для лечения воспаления и ишемического поражения

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4261285A (en) * 1984-06-01 1985-12-05 Tokyo Tanabe Company Limited 1-propanone derivatives
DE3433036A1 (de) * 1984-09-08 1986-03-20 Basf Ag, 6700 Ludwigshafen Piperidinderivate und diese enthaltende fungizide sowie verfahren zur bekaempfung von pilzen
ES2098248T3 (es) * 1989-05-17 1997-05-01 Pfizer Derivados de 2-piperidino-1-alcanoles como agentes antiisquemicos.
US4940789A (en) * 1989-10-10 1990-07-10 American Home Products Corporation 10,11-dihydro-5-alkyl-12-substituted-10,5-(iminomethano)-5H-dibenzo[a,d]cycloheptenes as neuroprotectant agents
DE69126438T2 (de) * 1990-10-15 1997-10-02 Astra Ab 2-phenyl- und 2-thienyl-(2)-piperidinderivate mit neuroprotektiven eigenschaften
SE9003652D0 (sv) * 1990-11-15 1990-11-15 Astra Ab New heterocyclic compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2649406C1 (ru) * 2017-09-21 2018-04-03 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) 3-n-замещенные борнилпропионаты, используемые в качестве ингибиторов вируса марбург

Also Published As

Publication number Publication date
CA2129771C (en) 2006-03-21
CN1105990A (zh) 1995-08-02
HUT70558A (en) 1995-10-30
NO943231L (no) 1995-03-03
TW281670B (ru) 1996-07-21
AU7149794A (en) 1995-03-16
BR9403418A (pt) 1996-09-03
EP0648744A1 (en) 1995-04-19
EP0648744B1 (en) 1998-01-21
DE69408078D1 (de) 1998-02-26
GR3026622T3 (en) 1998-07-31
JPH0782250A (ja) 1995-03-28
NO943231D0 (no) 1994-09-01
HU9402479D0 (en) 1994-10-28
IL110812A0 (en) 1994-11-11
NZ264320A (en) 1996-02-27
DK0648744T3 (da) 1998-09-21
FI944044A (fi) 1995-03-03
ES2113585T3 (es) 1998-05-01
FI944044A0 (fi) 1994-09-02
JP2610784B2 (ja) 1997-05-14
CA2129771A1 (en) 1995-03-03
KR950008481A (ko) 1995-04-17
CN1061035C (zh) 2001-01-24
ZA946529B (en) 1995-03-02
DE69408078T2 (de) 1998-07-09
ATE162520T1 (de) 1998-02-15
CZ210694A3 (en) 1995-08-16
FI107607B (fi) 2001-09-14
PL304863A1 (en) 1995-03-06
KR100360954B1 (ko) 2003-04-16

Similar Documents

Publication Publication Date Title
RU94031753A (ru) Производные фенилалканоламина
NO883587L (no) Fremgangsmaate for fremstilling av terapeutisk aktive indolderivater.
NO176356C (no) Analogifremgangsmåte for fremstilling av nye terapeutisk aktive pyrazolopyridinforbindelser
AU692090B2 (en) Novel 4,6-diarylpyrimidine derivatives and salts thereof
TR199800924T2 (xx) Quinoline t�revleri.
AU6601294A (en) Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
DK391289D0 (da) Indolderivater
PT928788E (pt) Compostos farmaceuticamente activos
FI860878A (fi) Aminosyraderivat och foerfarande foer deras framstaellning.
PL309874A1 (en) Novel derivatives of pyrrolocarbasol, method of obtaining them and pharmaceutical composition containing such derivatives
NO160297C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-oksoazetidinderivater
FI944823A (fi) Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
SI1216245T1 (en) Pharmaceutically active sulfonyl hydrazide derivatives
NO172893C (no) Analogifremgangsmaate for fremstilling av nye terapeutisk aktive cefem-forbindelser
ATE219085T1 (de) 2-beta-substituierte-6-alkylidenpenizillansäure derivate als beta-laktamase inhibitoren
FI935799A0 (fi) Arylsubstituerade heterocykliska foereningar
FI935798A0 (fi) Alkylsubstituerade heterocykliska foereningar
FI891807A0 (fi) Menetelmä terapeuttisesti aktiivisten oktahydropyrrolo-pyratsino/2,1-i/indol-2-oni-johdannaisten valmistamiseksi
NO174886C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive pyrrolidin-derivater
MY103509A (en) Indole derivatives.